Precision Health Clinical Trials
Genotyping of Ebus-tbna Supernant Cell-free Dna in Nsclc
Condition: Lung Cancer
Intervention: Other: Molecular analysis of surnatant
Sponsor: University Hospital, Toulouse
Not yet recruiting
Intervention: Other: Molecular analysis of surnatant
Sponsor: University Hospital, Toulouse
Not yet recruiting
For more information, visit the Study URL.
Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial
Conditions: Prostate Adenocarcinoma; Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8; Stage II Prostate Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8
Interventions: Procedure: Discussion; Radiation: Hypofractionated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Stereotactic Body Radiation Therapy
Sponsors: Jonsson Comprehensive Cancer Center; MiraDX
Recruiting
Interventions: Procedure: Discussion; Radiation: Hypofractionated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Stereotactic Body Radiation Therapy
Sponsors: Jonsson Comprehensive Cancer Center; MiraDX
Recruiting
For more information, visit the Study URL.
Sub-type Specific Genomic Mutations in sBOTs
Condition: Ovarian Neoplasm Epithelial
Intervention: Genetic: genomic mutations study
Sponsor: Universitair Ziekenhuis Brussel
Recruiting
Intervention: Genetic: genomic mutations study
Sponsor: Universitair Ziekenhuis Brussel
Recruiting
For more information, visit the Study URL.
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Conditions: Clear Cell Papillary Renal Neoplasm; Collecting Duct Carcinoma; Hereditary Leiomyomatosis and Renal Cell Carcinoma; Hereditary Papillary Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Unclassified Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8; Stage IV Renal Cell Cancer AJCC v8; Tubulocystic Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
Interventions: Drug: Pamiparib; Drug: Temozolomide
Sponsors: Jonsson Comprehensive Cancer Center; BeiGene; Driven To Cure
Recruiting
Interventions: Drug: Pamiparib; Drug: Temozolomide
Sponsors: Jonsson Comprehensive Cancer Center; BeiGene; Driven To Cure
Recruiting
For more information, visit the Study URL.
Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
Conditions: Head and Neck Cancer; Advanced Cancer; Metastatic Cancer; HNSCC; Squamous Cell Carcinoma
Intervention:
Sponsors: University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting
Intervention:
Sponsors: University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting
For more information, visit the Study URL.
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Conditions: BRCA1 Mutation; BRCA2 Mutation; Ovarian Cancer; Fallopian Tube Cancer; High Grade Serous Carcinoma
Intervention: Drug: Talazoparib Oral Capsule
Sponsors: Brown University; Pfizer; Lifespan
Recruiting
Intervention: Drug: Talazoparib Oral Capsule
Sponsors: Brown University; Pfizer; Lifespan
Recruiting
For more information, visit the Study URL.
SH-DS01 on Fecal Metagenomic Stability
Condition: Irritable Bowel Syndrome
Intervention: Drug: DS-01
Sponsors: Beth Israel Deaconess Medical Center; Seed Health
Recruiting
Intervention: Drug: DS-01
Sponsors: Beth Israel Deaconess Medical Center; Seed Health
Recruiting
For more information, visit the Study URL.
Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma (PRE-MERIDIAN)
Conditions: Cancer; Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer
Intervention:
Sponsors: University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting
Intervention:
Sponsors: University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting
For more information, visit the Study URL.
Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan
Condition: Metastatic Castration-sensitive Prostate Cancer
Intervention: Drug: Apalutamide
Sponsors: Kindai University; Janssen Pharmaceutical K.K.
Recruiting
Intervention: Drug: Apalutamide
Sponsors: Kindai University; Janssen Pharmaceutical K.K.
Recruiting
For more information, visit the Study URL.
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
Conditions: Biliary Tract Neoplasms; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Colorectal Cancer; Gastrointestinal Stromal Tumors; Pancreatic Cancer; Neuroendocrine Tumors; Unknown Primary Cancer; Digestive Cancer
Interventions: Drug: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.; Drug: Other Therapy
Sponsors: Peking University; Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China
Recruiting
Interventions: Drug: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.; Drug: Other Therapy
Sponsors: Peking University; Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China
Recruiting
For more information, visit the Study URL.